Summary

Asia Pacific Influenza Diagnostics Market is valued at approximately USD 330 million in 2023 and is anticipated to grow with a healthy growth rate of more than 7.86% over the forecast period 2024-2032. Influenza diagnostics refers to the methods and technologies used to identify and diagnose influenza virus infections in persons. These diagnostics are critical to public health as they enable early detection, treatment, and prevention of influenza transmission. Moreover, there has been a growing demand for POCT (Point-of-Care Testing) devices in the Asia Pacific region due to their ability to provide rapid and accurate results, especially in remote and resource-limited settings. POCT devices offer advantages such as quick turnaround time, ease of use, and minimal sample processing requirements, making them increasingly popular for influenza diagnosis, this anticipated to support the Influenza Diagnostics Market.

Moreover, the Asia Pacific region, with its dense population and varied climates, often experiences influenza outbreaks. The rising incidence of influenza drives the demand for diagnostics to accurately identify and manage cases. Also, governments and healthcare authorities in many Asia Pacific countries are implementing various initiatives to control and prevent the spread of influenza. These initiatives often include vaccination campaigns and investments in diagnostic infrastructure, which contribute to market growth. Additionally, other factors that support the market growth are growing awareness and healthcare infrastructure, supportive government initiatives, increasing research and development activities, growing research and development activities, rising demand for point-of-care testing, and increasing healthcare spending. However, the lack of skilled professionals, and stringent regulatory frameworks are anticipated to hinder the market growth during the forecast period 2024-2032.

The key Countries considered for the Asia Pacific Influenza Diagnostics market study includes China, India, Japan, South Korea, Australia and Rest of Asia Pacific. In 2023, China was the largest regional market. The Chinese government has been actively promoting healthcare infrastructure development and disease control measures. Initiatives aimed at controlling infectious diseases such as influenza drive the adoption of diagnostic tests. Also, with the rise in population density and increased globalization, the spread of influenza viruses has become more common. This increases the demand for diagnostic tests to identify and manage outbreaks effectively. Moreover, India is expected to grow with the highest CAGR during the forecast period 2024-2032.

Major market player included in this report are:
Abbott Laboratories
SD Biosensor Inc
3B BlackBio Dx Limited
Company 4
Company 5
Company 6
Company 7
Company 8
Company 9
Company 10

The detailed segments and sub-segment of the market are explained below:
By Test Type
RIDT
RT-PCR
Cell Culture
Others

By End Use
Hospitals
POCT
Laboratories
By Region:
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Years considered for the study are as follows:
Historical year – 2022
Base year – 2023
Forecast period – 2024 to 2032

Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and country level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market

ページTOPに戻る

Table of Contents

Chapter 1. Asia Pacific Influenza Diagnostics Market Definition and Research Assumptions
1.1. Research Objective
1.2. Market Definition
1.3. Research Assumptions
1.3.1. Inclusion & Exclusion
1.3.2. Limitations
1.3.3. Supply Side Analysis
1.3.3.1. Availability
1.3.3.2. Infrastructure
1.3.3.3. Regulatory Environment
1.3.3.4. Market Competition
1.3.3.5. Economic Viability (Consumer’s Perspective)
1.3.4. Demand Side Analysis
1.3.4.1. Regulatory frameworks
1.3.4.2. Technological Advancements
1.3.4.3. Environmental Considerations
1.3.4.4. Consumer Awareness & Acceptance
1.4. Estimation Methodology
1.5. Years Considered for the Study
1.6. Currency Conversion Rates

Chapter 2. Executive Summary
2.1. Asia Pacific Influenza Diagnostics Market Size & Forecast (2022- 2032)
2.2. Regional Summary
2.3. Segmental Summary
2.3.1. By Test Type
2.3.2. By End Use
2.4. Key Trends
2.5. Recession Impact
2.6. Analyst Recommendation & Conclusion
Chapter 3. Asia Pacific Influenza Diagnostics Market Dynamics
3.1. Market Drivers
3.2. Market Challenges
3.3. Market Opportunities
Chapter 4. Asia Pacific Influenza Diagnostics Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model
4.1.7. Porter’s 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top investment opportunity
4.4. Top winning strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Asia Pacific Influenza Diagnostics Market Size & Forecasts by Test Type 2022-2032
5.1. RIDT
5.2. RT-PCR
5.3. Cell Culture
5.4. Others
Chapter 6. Asia Pacific Influenza Diagnostics Market Size & Forecasts by End Use 2022-2032
6.1. Hospitals
6.2. POCT
6.3. Laboratories
Chapter 7. Asia Pacific Influenza Diagnostics Market Size & Forecasts by Country 2022-2032
7.1. China Influenza Diagnostics Market
7.1.1. Test Type breakdown size & forecasts, 2022-2032
7.1.2. End Use breakdown size & forecasts, 2022-2032
7.2. India Influenza Diagnostics Market
7.3. Japan Influenza Diagnostics Market
7.4. Australia Influenza Diagnostics Market
7.5. South Korea Influenza Diagnostics Market
7.6. Rest of Asia Pacific Influenza Diagnostics Market
Chapter 8. Competitive Intelligence
8.1. Key Company SWOT Analysis
8.1.1. Company 1
8.1.2. Company 2
8.1.3. Company 3
8.2. Top Market Strategies
8.3. Company Profiles
8.3.1. Abbott Laboratories
8.3.1.1. Key Information
8.3.1.2. Overview
8.3.1.3. Financial (Subject to Data Availability)
8.3.1.4. Product Summary
8.3.1.5. Market Strategies
8.3.2. SD Biosensor Inc
8.3.3. 3B BlackBio Dx Limited
8.3.4. Company 4
8.3.5. Company 5
8.3.6. Company 6
8.3.7. Company 7
8.3.8. Company 8
8.3.9. Company 9
8.3.10. Company 10
Chapter 9. Research Process
9.1. Research Process
9.1.1. Data Mining
9.1.2. Analysis
9.1.3. Market Estimation
9.1.4. Validation
9.1.5. Publishing
9.2. Research Attributes